Navigation Links
Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
Date:11/9/2010

ially successful or will effectively enhance our businesses or their market value, or that the MedPodium product line can be successfully broadened to include additional healthy lifestyle opportunities, or that we can effectively promote commercialization of our products on our own or through third parties; that improvements in the formulation or use of Generx will be commercially practicable, or that Generx could be successfully advanced as a therapeutic in developing markets or that the results of studies in such markets could be used to advance or broaden the commercialization of Generx in the U.S. or other markets; that Nitric Oxide or other technologies we investigate can be used to effectively expand or improve our product portfolio; that our product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that our clinical study programs can be conducted and completed in an efficient and successful manner; that we can develop a DNA-based orthobiologics product portfolio; that the FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our depen
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
2. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
3. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
4. Cardium Regains Listing Compliance With NYSE Amex
5. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
6. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
7. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
8. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
9. Cardium Completes $6.0 Million Registered Direct Offering
10. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
11. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... group leader Yung-Eun Sung has announced that they ... nitrogen-doped graphenes which can be applied as high ... Yung-Eun Sung is both a group leader at ... Basic Science* (IBS) and a professor at the ... significance with regards to the development of relative ...
(Date:7/24/2014)... prefer to settle into equilibriuma state of unchanging ... realm of non-equilibrium conditions where new possibilities lie. ... phases, such as temperature fluctuations, freezing and melting, ... their body temperature, airplanes to fly, and the ... But even though these conditions exist naturally and ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL) today ... for its asthma management product, Aridol., "This ... Pharmaxis Chief,Executive Officer Dr Alan Robertson. "Korea is ... Aridol in Asia. There are an estimated 2.5 ...
... 16 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), ... year ended November 30, 2007. All dollar amounts ... At November 30, 2007, our cash and ... at November 30, 2006. The change in,our cash ...
... 16 Bristol-Myers Squibb,Company (NYSE: BMY ) will ... 2007 on Thursday, January 31. During a 10 a.m. ... financial information and will,address inquiries from investors and analysts., ... listen to a live,webcast of the call at ...
Cached Biology Technology:Pharmaxis' Aridol Gains First Asian Approval 2Vasogen Announces 2007 Year-End Results 2Vasogen Announces 2007 Year-End Results 3Vasogen Announces 2007 Year-End Results 4Vasogen Announces 2007 Year-End Results 5Vasogen Announces 2007 Year-End Results 6Vasogen Announces 2007 Year-End Results 7Vasogen Announces 2007 Year-End Results 8Vasogen Announces 2007 Year-End Results 9Vasogen Announces 2007 Year-End Results 10Vasogen Announces 2007 Year-End Results 11
(Date:7/25/2014)... link between autism and disrupted brain development is ... disease, and is largely unknown. However, thanks to ... (SFARI), George Washington University (GW) researcher Anthony-Samuel LaMantia, ... and in-depth answers to these key questions in ... professor of pharmacology and physiology at the GW ...
(Date:7/25/2014)... research at the University of Adelaide has opened the way ... to powdery mildew. , In Australia, annual barley production is ... Powdery mildew is one of the most important diseases of ... have discovered the composition of special growths on the cell ... fungus into the leaf. , The research, by the ARC ...
(Date:7/25/2014)... MOResearchers at the Stowers Institute for Medical Research ... pheromone receptors, and found pheromones crucial to triggering the ... of receptors helps a male mouse detect pheromones that ... of receptors lets him know if the female mouse ... pheromones are critical to trigger mating. Stowers, researchers believe ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2New hope for powdery mildew resistant barley 2It takes two to court 2It takes two to court 3
... wife doesn,t feel good on the Pill. He,d like to have ... responsibility for contraception. But they want another child, so vasectomy is ... drops his electric car off for a quick charge, he pops ... minutes of ultrasound treatment, for 6 months of contraception. Sound ...
... to help assess the spread and impact of the Deepwater ... the request of U.S. disaster response agencies. As part ... instrumented research aircraft the Earth Resources-2 (ER-2) to the Gulf ... observations and conducting additional data processing to assist the National ...
... attempt to silence the biochemical conversations that disease-causing bacteria ... a study in ACS, monthly journal, Biomacromolecules , ... soak up the substances that bacteria produce and pass ... and colleagues point out that more and more disease-causing ...
Cached Biology News:No more pills: Male contraceptive takes new approach 2No more pills: Male contraceptive takes new approach 3No more pills: Male contraceptive takes new approach 4NASA deploys planes, targets satellites to aid in oil spill response 2NASA deploys planes, targets satellites to aid in oil spill response 3
RORgamma (S-14)...
... Sophions newly introduced QPatch HT is taking ... more powerful level. With its ability to generate ... HT is enabling new screening paradigms in ion ... clamping with the same high quality afforded by ...
... aptamer screening and binding optimization and built ... on-chip synthesis platform. These microarrays are available ... Microarray Service. Probe Content ... than 1500 known aptamer sequences. Add up ...
... provides a comprehensive epitope analysis service ... on Paraflo microfluidic chips for immunological ... This comprehensive service includes assistance with ... sample(s) provided by you, single or ...
Biology Products: